Paul Tudor Jones Global Blood Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $6.59 Million - $13.9 Million	203,528 Added 437.1%	250,091 $17 Million
Q2 2022 Aug 15, 2022	BUY	$22.3 - $37.39 $747,852 - $1.25 Million	33,536 Added 257.43%	46,563 $1.49 Million
Q1 2022 May 16, 2022	SELL	$25.68 - $35.59 $1.15 Million - $1.6 Million	-44,919 Reduced 77.52%	13,027 $451,000
Q4 2021 Feb 14, 2022	SELL	$24.9 - $40.26 $756,711 - $1.22 Million	-30,390 Reduced 34.4%	57,946 $1.7 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $2.25 Million - $3.3 Million	88,336 New	88,336 $2.25 Million
Q2 2018 Aug 14, 2018	SELL	$38.7 - $50.15 $231,813 - $300,398	-5,990 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$39.6 - $65.9 $101,970 - $169,692	-2,575 Reduced 30.06%	5,990 $289,000
Q4 2017 Feb 14, 2018	SELL	$29.7 - $45.7 $24,502 - $37,702	-825 Reduced 8.79%	8,565 $337,000
Q3 2017 Nov 14, 2017	BUY	$25.1 - $31.05 $235,689 - $291,559	9,390	9,390 $292,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.